Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-?
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Ischemic Stroke
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: multicenter, prospective, randomized, open label, blinded-endpoint (PROBE)?Parallel controls?Non-inferiorityMasking: Single (Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
To test the hypothesis that rhTNK-tPA is non-inferior to alteplase in thrombolysis treatment when administered within 4.5 hours of ischemic stroke onset.
To test the hypothesis that rhTNK-tPA is non-inferior to alteplase in thrombolysis treatment when administered within 4.5 hours of ischemic stroke onset.
Tracking Information
- NCT #
- NCT04797013
- Collaborators
- Guangzhou Recomgen Biotech Co., Ltd.
- Investigators
- Study Director: Wei Sun IRB of Beijing Tiantan Hospital,Capital Medical University
Get Well Soon